SciELO - Scientific Electronic Library Online

 
vol.36 número1Terá a melatonina uma ação fotoprotetora cutânea?: Uma revisão baseada na evidênciaPolipose adenomatosa familiar: um relato de caso índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Portuguesa de Medicina Geral e Familiar

versión impresa ISSN 2182-5173

Resumen

LONGRAS, Carla; CAVADAS, Luís Filipe  y  CORDEIRO, Cátia. The impact of intensive LDL-c reduction on morbidity and mortality in patients with diabetes: an evidence-based review. Rev Port Med Geral Fam [online]. 2020, vol.36, n.1, pp.57-63. ISSN 2182-5173.  https://doi.org/10.32385/rpmgf.v36i1.12574.

Objective: The aim of this review is to determine the impact of LDL-c reduction with statins on morbidity and mortality in patients with diabetes Methods: The search included studies, published between 1st January 2008 and 19th July 2018, in English, with the MeSH terms: Hydroxymethylglutaryl-CoA Reductase Inhibitors AND diabetes mellitus AND low-density lipoprotein AND morbidity; Hydroxymethylglutaryl-CoA Reductase Inhibitors AND diabetes mellitus AND low-density lipoprotein AND mortality. To assign the levels of evidence and recommendation forces, the American Academy of Family Physicians (AAFP) SORT scale was used. Results: A total of 174 articles were identified and three were selected: one meta-analysis and two clinical trials. The meta-analysis included 14 studies and demonstrated the benefit of statins in reducing the incidence of major vascular events in about 1/5 per mmol/L of LDL-c reduction. In the prospective clinical trial, the reduction of events was greater in the group with greater LDL-c reductions but there were no differences in all-cause mortality. In the retrospective clinical trial, there was a reduction of cardiovascular risk and all-cause mortality in the group assigned to statins compared to the control group. Conclusions: There were several limitations in the included studies, namely heterogeneous populations, short follow-up and methodological shortcomings. There seems to be a benefit in taking statins to lower LDL-c levels on the reduction of morbidity, cardiovascular events and all-cause mortality (strength of recommendation B). However, there is limited evidence about the recommended target LDL-c levels.

Palabras clave : Hydroxymethylglutaryl-CoA reductase inhibitors; Diabetes mellitus; Low-density lipoprotein; Morbidity; Mortality.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons